IFF Recognizes Anne Flipo with Master Perfumer Designation
8.2.2019 00:15:00 EET | Business Wire | Press release
Regulatory News:
International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), named Anne Flipo Master Perfumer, where she joins the ranks of the world’s finest scent artists. The Company’s designation recognizes perfumers who have demonstrated consistent and outstanding levels of creativity and craftsmanship in the art of perfumery, and exceptional leadership in and measurable impact on the industry. Ms. Flipo is the fifth perfumer at IFF recognized with the prestigious title, which was established in 2013.
“One of the great distinctions about IFF is the sheer quality and extraordinary talent of our people,” said Andreas Fibig, IFF Chairman & CEO. “Our perfumers create fragrances that form the sensory backdrop to people’s lives – something Anne understands well. I am thrilled at her recognition, not only for her lifetime of achievements thus far, but for the great things we continue to expect from her.”
Raised in Picardy, France, Ms. Flipo’s childhood was scented with wildflowers and vegetable gardens. She was fascinated by nature, cooking, and music, influences which remain with her today. After her baccalaureate, she joined ISIPCA, the legendary school for perfume, flavors, and cosmetics, to begin her training for a career in flavors. While an apprentice, she encountered essential oils for perfumery and realized that a life in fragrances is where her future would be made. Once ensconced in the industry, Ms. Flipo worked alongside some of the greats in the profession, each of whom left their influence on the young perfumer. She honed her personal style and approach and as she did, enjoyed a series of successes that established her as a perfumer to watch. Since joining IFF in 2004, her list of “wins” with extraordinary and iconic brands has only grown.
Ms. Flipo said, “I would like to speak about my 15 years with IFF. The life of a perfumer can be challenging, but IFF gave me the room to come into my own skin. It forced me to be the master of my own life, to let go of the fear, to embrace who I am, and discover independence.” Ms. Flipo continued, “IFF supports you when you challenge yourself, and it treats us as individuals, rather than a machine. At IFF, you are part of a team, where I know I belong, and where I know that what I bring is unique and valued. I was able to overcome any obstacles thanks to the outstanding human fabric of the company, which holds everything together, and creates common values which we all stand for: passion, simplicity and kindness… and a bit of madness too!”
Ms. Flipo industry recognitions include the Cosmetique Magazine Perfumer of the Year award in 2014 and Cosmetic Executive Women (CEW) France Achiever Award for Creation in 2016. In addition, many of her fragrance creations have been the recipients of the Fragrance Foundation Awards in both the US and Europe.
“Anne’s admirers are countless,” said Nicolas Mirzayantz, Divisional CEO of Scent. “including her contemporaries, mentees, clients and endless consumers. Every one of her fragrance designs is a vivid combination of her passionate heart and curious, creative mind.” Mr. Mirzayantz continued, “Like her fellow Master Perfumers, Anne is committed to mentoring the next generation of perfumers as they take their exciting and distinct journeys. Their genuine appreciation of her vast knowledge, inspiring spirit and dynamic instruction supports their dreams to connect to the world through scent. I am truly thrilled to recognize Anne with this well-deserved honor.”
# # #
Meet IFF
International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF) is a leading innovator of scent, taste, and nutrition, with over 110 manufacturing facilities, 100 R&D centers, and 33,000 customers globally. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for exploration drives us to co-create unique products that consumers experience in more than 150,000 unique products sold annually. Our 13,000 team members globally take advantage of leading consumer insights, naturals exploration, research and development, creative expertise, and customer intimacy to develop differentiated offerings for consumer products.
Learn more at www.iff.com, Twitter , Facebook, Instagram, and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190207005799/en/
Contact information
Michael DeVeau
Head of Investor Relations and Communications &
Divisional CFO, Scent
212.708.7164
Michael.DeVeau@iff.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 18:51:00 EEST | Press release
Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 17:25:00 EEST | Press release
Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensuring your investment is delivering.” The rapid growth of the residential solar market created a growing population of “orphaned” solar sy
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
